Skip to Content
Merck
CN
  • Serum carnosinase 1, an early indicator for incident microalbuminuria in type 1 diabetes.

Serum carnosinase 1, an early indicator for incident microalbuminuria in type 1 diabetes.

Journal of diabetes and metabolic disorders (2024-06-27)
Jiedong Qiu, Benito A Yard, Bernhard K Krämer, Henk J G Bilo, Aimo Kannt, Harry van Goor, Peter R van Dijk
ABSTRACT

Carnosinase (CN1) polymorphisms have been linked to diabetic kidney disease (DKD), as CN1 degrades dipeptides which scavenge oxidative metabolites and prevent the formation of advanced glycation end-products. In this work, we studied the association between serum CN1, the systemic redox status and long-term renal outcome in type 1 diabetes. Serum CN1 was measured in a prospective type 1 diabetes cohort (n = 218) with a 16-year follow-up. A total of 218 patients treated at the Diabetes Outpatient Clinic of the Weezenlanden Hospital (nowadays Isala Hospital, Zwolle, The Netherlands) were included in this analysis. We assessed whether serum CN1 was associated with renal function and development of DKD as well as other diabetic complications. At baseline, age, systemic redox status and N-terminal pro brain-natriuretic peptide (NT-proBNP) were associated with serum CN1 concentration (p < 0.05). During follow-up, CN1 concentration in the middle tertile was associated with less incident microalbuminuria (odds ratio = 0.194, 95% C.I.: 0.049-0.772, p = 0.02) after adjustment for age, systemic redox status, NT-proBNP and sex. Serum CN1 could predict incident microalbuminuria and may be used as a novel parameter to identify patients at risk for DKD.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-CNDP1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution